Falk Gastro Info 10/2014

Video

 

 

 

Dilation of a sigma stenosis with a stent

 

Video report of live endoscopies performed at the Endo Club Nord 2013 in Hamburg, November 1 – 2, 2013. © Dr. Falk Pharma GmbH, Freiburg.

 

Video recording of the dilation of 6 cm sigmoid stenosis caused by a carcinoma by placing a stent. The procedure was performed during Endo Club Nord 2013 by PD. Dr. Siegbert Faiss, Asklepios Hospital Barmbek.

 

 

Please switch on your loudspeakers!

 

 

 

 

Link to Falk Mediacenter:

http://media.falkfoundation.de/index.php?id=78&L=1

 

Link to the video directly:

http://media.drfalkpharma.de/fileadmin/media/140930_ECN_02_ENG_FINAL_mittel.mp4

 

 

 

 

 

Preview images:

 

180 x 112 pixels

http://www.drfalkpharma.de/fileadmin/media/Video/Sigmastenose_ECN_180.jpg

 

580 x 350 pixels

http://www.drfalkpharma.de/fileadmin/media/Video/Sigmastenose_ECN_580.jpg

 

 

 

Bowel

 

 

Text:

 

Billioud V et al, J Crohns Colitis. 2013;7(11):853–67

 

Preoperative anti-TNF use slightly increases the occurrence of overall postoperative complications in inflammatory bowel disease patients, and particularly infectious complications in Crohn’s disease patients. Postoperative complications are not increased in ulcerative colitis.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18862#c26601

 

 

Text:

 

Khan N et al, Gastroenterology. 2013;145(5):1007–15

 

Based on a retrospective, nationwide cohort study in the US, patients with ulcerative colitis have a 4-fold increase in risk of lymphoma while being treated with thiopurines compared with patients who have not been treated with thiopurines. The risk increases gradually for successive years of therapy. Discontinuing thiopurine therapy reduces the risk of lymphoma.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18862#c26602

 

 

Text:

 

Sandborn WJ et al, Gastroenterology. 2014;146(1):85–95

Sandborn WJ et al, Gastroenterology. 2014;146(1):96–109

 

Treatment with subcutaneous golimumab (100 mg/50 mg/50 mg, or 200 mg/100 mg/100 mg, or 400 mg/200 mg/200 mg, 2 weeks apart) induces clinical response (51–54% vs. 30% for placebo), remission, and mucosal healing at week 6, and increases quality of life in larger percentages of patients with active ulcerative colitis than placebo. Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who had responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg golimumab had clinical remission and mucosal healing at weeks 30 and 54. Safety was consistent with that reported for other TNF-α antagonists and golimumab in other approved indications.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18862#c26603

 

 

Liver
Biliary Tracts

 

 

Text:

 

Karkhanis J et al, Hepatology. 2014;59(2):612–21

 

Corticosteroids did not improve overall survival or spontaneous survival in drug-induced, indeterminate, or autoimmune acute liver failure and were associated with lower survival in patients with the highest MELD scores.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18862#c26604

 

 

Text:

 

Fried MW et al, Hepatology. 2013;58(6):1918–29

 

Simeprevir administered once-daily in combination with pegylated interferon-α2a and ribavirin significantly improves the sustained virologic response rates, compared with pegylated interferon-α2a and ribavirin alone, and allows the majority of patients to shorten their therapy duration to 24 weeks.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18862#c26605

 

 

Text:

 

Kitrinos KM et al, Hepatology. 2014;59(2):434–42

 

Tenofovir disoproxil fumarate monotherapy maintains effective suppression of HBV DNA through 288 weeks of treatment with no evidence of resistance to the drug.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18862#c26606

 

 

 

 

 

 

 

 

 

 

 

Oesophagus

Stomach

Duodenum

 

 

Text:

 

Bae SE et al, Am J Gastroenterol. 2014;109(1):60–7

 

Successful Helicobacter pylori eradication may reduce the occurrence of metachronous gastric cancer after endoscopic resection in patients with early gastric cancer.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18862#c26607

 

 

Text:

 

Singh S et al, Clin Gastroenterol Hepatol. 2013;11(11):1399–412

 

Central adiposity, independent of body mass index, is associated with esophageal inflammation (erosive esophagitis), metaplasia (Barrett’s esophagus), and neoplasia (esophageal adenocarcinoma). Its effects are mediated by reflux-dependent and reflux-independent mechanisms.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18862#c26608

 

 

Text:

 

McNicholl AG et al, Gut. 2014;63(2):244–9

 

10 days concomitant therapy of infection with Helicobacter pylori with omeprazole, amoxicillin, clarithromycin, and metronidazole led to a slightly better eradication rate of 91% than sequential therapy with the same substances (86%). Both therapies showed an acceptable safety profile.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18862#c26609

 

 

 

 

 

 

 

Pancreas

 

 

Text:

 

Bhoo-Pathy N et al, Clin Gastroenterol Hepatol. 2013;11(11):1486–92

 

Based on an analysis of data from the European Prospective Investigation into Nutrition and Cancer cohort, total coffee, decaffeinated coffee, and tea consumption are not related to the risk of pancreatic cancer.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18862#c26610


 

 

Current Falk literature:

 

 

What you should know about gallstone treatment

Compiled by: M. Sackmann

(31 pages)

U85e

 

Picture:

http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Patientenratgeber/Titelblatt/U85e_13-9-14.jpg

 

PDF:

http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Patientenratgeber/PDF/U85e_13-9-14.pdf

 

 

Order by email (Please replace text by your email address):

 

mailto:text?subject=FGI%210%2F2014:%20Ordering%20of%20brochure%20U85e&body=Please%20send%20the%20brochure%20to%20the%20following%20address:%0A%0A